Kyverna Shares Rise After FDA Gives Special Designation to Stiff-Person Treatment
By Stephen Nakrosis
Shares of Kyverna Therapeutics rose after hours on Monday, following news that the company's treatment of refractory stiff-person syndrome got a regenerative medicine advanced therapy designation for the Food and Drug Administration.
The stock was recently up 8.9% at $10.80. Shares finished the day's regular session with a 1.2% gain and are down about 57% since listing on Nasdaq in February.
KYV-101's designation as regenerative medicine advanced therapy allows for accelerated approval based on intermediate endpoints. The designation is aimed at treating serious or life-threatening conditions.
Refractory stiff-person syndrome is a rare autoimmune disorder with symptoms including painful muscle rigidity and violent spasms. The National Organization for Rare Disorders said one estimate places the incidence at one in a million.
Kyverna said KYV-101 is being evaluated in trials in the U.S. and Germany across rheumatology and neurology, two broad areas of autoimmune disease.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 15, 2024 18:57 ET (22:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst